Role of N-acetyl-aspartyl-glutamate in schizophrenia model;Úloha N-acetyl-aspartyl-glutamátu v modelu schizofrenie

Psychiatrie

Volumn 5, Issue SUPPL. 3, 2001, Pages 10-14

  Stastny F ^a   Pliss, L ^a   Bubenikova V ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Glutamatergic dysfunction; N acetyl aspartyl glutamate; Neurodevelopmental hypothesis of schizophrenia

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL FEATURE; CONFERENCE PAPER; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA;

EID: 0034820336     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Glutamátem aktivované iontové kanály
2. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
3. Absence of neurodegeneration and neuronal injury in the cerebral cortex in a sample of elderly patients with schizophrenia
4. Metabotropic glutamate receptors modify ionotropic glutamate responses in neocortical pyramidal cells and interneurons
5. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia
6. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22
7. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
8. Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393
9. The glutamatergic dysfunction hypothesis for schizophrenia
10. The nagging question of the function of N-acetylaspartylglutamate
11. NMDA receptor subunits: Diversity, development and disease
12. The neurodevelopmental hypothesis of schizophrenia: Clinical evidence and animal models
13. Glycine agonists. What can they teach us about schizophrenia
14. Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions
15. The NR1 subunit of the N-methyl-D-aspartate receptor can be efficiently expressed alone in the cell surface of mammalian cells and is required for the transport of the NR2 subunit
16. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effect of schizophrenia
17. com NR2A, NR2B, NR2C, NR2D and NR3A
18. Glutamate receptors in schizophrenia and antipsychotic drugs
19. The neuropathology of schizophrenia. A critical review of the data and their interpretation
20. Inhibiting neuronal migration by blocking NMDA receptors in the embryonic rat cerebral cortex: A tissue culture study
21. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain
22. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
23. Recent advances in the phencyclidine model of schizophrenia
24. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia
25. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective
26. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat
27. Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats
28. Glutamate receptor expression in schizophrenic brain
29. Reversal of phencyclidine effects by a group II metabotropic receptor agonist in rats
30. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
31. Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum
32. N-acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system
33. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: Mortality and millivolts
34. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia patients and a new hypothesis of glutamatergic neuronal dysfunction
35. Neurotoxicity of NAAG in vivo is sensitive to NMDA antagonists and mGluR II ligands
36. Characterization of hippocampal neurodegeneration after intracerebroventricular administration of N-acetyl-aspartyl-glutamate
37. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS, NMR
38. The neuropathology of schizophrenia
39. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus
40. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats
41. Actions of butyrophenones and other antipsychotic agents at NMDA receptors: Relationship with clinical effects and structural considerations
42. Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine
43. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
44. N-acetylated α-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin
45. Schizophrenia: Genes and environment
46. Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays
47. Cell biology of the hippocampal formation in schizophrenia
48. Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain
49. Up-regulation of N-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists
50. Expression of NMDA receptor subunit mRNA after MK-801 treatment in neonatal rats
51. Inhibitory glutamatergic regulation of evoked dopamine release in striatum
52. Apoptosis in the nervous system